Drug Development Costs About $1.7 Billion

Mulliν, Rick

doi:10.1021/cen-v081n050.p008a

Cited by 25 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When investment and capitalization costs are included this estimate rises to $802 million. A more recent study by Bain & Co. put the costs at $1.7 billion (Gilbert et al, 2003;Mullin, 2003). Regardless of the actual costs, these impressively large numbers, coupled with the observation that only 21% of drugs that enter phase I clinical trials make it to the marketplace, underscore the difficulty of enticing the investment community to fund research for rare diseases for which recovery of development costs seems unlikely.…”

Section: Costs Of Developing Therapeuticsmentioning

confidence: 99%

Challenges in Developing Therapies for Rare Diseases Including Pachyonychia Congenita

Kaspar

2005

Journal of Investigative Dermatology Symposium Proceedings

View full text Add to dashboard Cite

show abstract

Section: Costs Of Developing Therapeuticsmentioning

confidence: 99%

Challenges in Developing Therapies for Rare Diseases Including Pachyonychia Congenita

Kaspar

2005

Journal of Investigative Dermatology Symposium Proceedings

View full text Add to dashboard Cite

show abstract

“…These costs include commercialization costs (Gilbert et al 2003;Mullin 2003;Liang and Mackey 2011), litigation and drug-recall costs (Klein and Tabarrok 2003), and general costs to society (Lazarou et al 1998;Rawlins 2004). Commercialization costs for new drug to be about $250 million per approved drugs (Gilbert et al 2003;Dickson and Gagnon 2004a, b), are high mainly because most ''new'' drugs approved are The DrugBank database is a blended bioinformatics and chemo informatics resource that combines detailed drug (i.e., chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e., sequence, structure, and pathway) information 2 Therapeutic target DB (Zhu et al 2012) The therapeutic target database (TTD) is a drug database designed to provide information about the known therapeutic protein and nucleic acid targets described in the literature, the targeted disease conditions, the pathway information and the corresponding drugs/ligands directed at each of these targets 3 STITCH (Kuhn et al 2010) STITCH ('search tool for interactions of chemicals') is a searchable database that integrates information about interactions from metabolic pathways, crystal structures, binding experiments and drug-target relationships.…”

Section: Promote Novel/new Drug Developmentmentioning

confidence: 99%

Role of bioinformatics and pharmacogenomics in drug discovery and development process

Katara

2013

Netw Model Anal Health Inform Bioinforma

View full text Add to dashboard Cite

Drug discovery and development is a complex, high risk, time consuming and potentially highly rewarding process. Pharmaceutical companies literally burn millions of dollar per drug to bring it to the market. The development of a new drug requires a technological expertise, human resources and huge capital investment. It also requires strict adherence to regulations on testing and manufacturing standards before a new drug comes into market and can be used in the general population, in fact, some time it fails to come into market. All these factors just increase the cost for a new chemical entity research and development. Two branches which made positive impact on drug designing process and reduce the overall cost and risk are Bioinformatics and Pharmacogenomics. Their practice in drug designing process made positive effect on overall process and they can accelerate various steps of drug designing, and reduce the cost and over all time. Current note focusses on the role of bioinformatics and pharmacogenomics in drug discovery and development process.

show abstract

“…In 1991, the estimated cost of "bringing a new medicine to the market" was USD $231 million [66]; current estimates range from over USD $800 million to $1.7 billion [67]. In considering costs, allowance must be made for the considerable costs of research and development devoted to the many potential leads and candidates which eventually fail to become commercial products, as well as the substantial costs of "borrowing money" to finance these very expensive enterprises.…”

Section: Development Costs and Timeframementioning

confidence: 99%

International collaboration in drug discovery and development from natural sources

Cragg¹,

Newman²

2005

Pure and Applied Chemistry

View full text Add to dashboard Cite

Nature has been a source of medicinal agents for thousands of years, and an impressive number of modern drugs have been isolated from natural sources, particularly plants, with many based on their use in traditional medicine. The past century, however, has seen an increasing role played by microorganisms in the production of the antibiotics and other drugs for the treatment of serious diseases, and more recently, marine organisms have proved to be a rich source of novel bioactive agents. Natural products will continue to play a crucial role in meeting this demand through the expanded investigation of the world's biodiversity, much of which remains unexplored. By using medicinal chemistry, and combinatorial chemical and biosynthetic technology, novel natural product leads will be optimized on the basis of their biological activities to yield effective chemotherapeutic and other bioactive agents. With much of the biological diversity found in tropical and subtropical regions, the investigation of these resources requires multidisciplinary international collaboration in the discovery and development process. Such collaboration can result in substantial short-term benefits accruing to source countries, with the potential for the generation of significant longer-term benefits in the select cases of those agents that proceed into advanced development, and possible commercialization.

show abstract

Drug Development Costs About $1.7 Billion

Cited by 25 publications

References 0 publications

Challenges in Developing Therapies for Rare Diseases Including Pachyonychia Congenita

Challenges in Developing Therapies for Rare Diseases Including Pachyonychia Congenita

Role of bioinformatics and pharmacogenomics in drug discovery and development process

International collaboration in drug discovery and development from natural sources

Contact Info

Product

Resources

About